肝星状细胞
非酒精性脂肪肝
自噬
肝硬化
纤维化
肝纤维化
癌症研究
生物
内分泌学
医学
内科学
脂肪肝
生物化学
细胞凋亡
疾病
作者
Ying Cao,Weili Mai,Rui Li,Shuwei Deng,Lan Li,Yanxi Zhou,Qiushi Qin,Yue Zhang,Xingang Zhou,Ming Han,Pu Liang,Yonghong Yan,Hao Yu,Wen Xie,Jie Yan,Liuluan Zhu
标识
DOI:10.1007/s00018-022-04319-w
摘要
The pathogenesis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) remains unclear and the effective treatments have not been explored yet. The activation of hepatic stellate cells (HSCs) is considered as the most critical factor in the progression of liver fibrosis and cirrhosis. Autophagy has recently been identified as a new mechanism to regulate HSC activation. Here, we found that liver macrophages were polarized toward type 2 (M2) during the progression of nonalcoholic steatohepatitis (NASH) and liver fibrosis in both patients and NAFLD mice. Using the methionine–choline-deficient (MCD) diet NAFLD murine model and the in vitro cell culture system, we identified that the M2 macrophages promoted HSC autophagy by secreting prostaglandin E2 (PGE2) and binding its receptor EP4 on the surface of HSCs, which consequently enhanced HSC activation, extracellular matrix deposition, and liver fibrosis. Mechanistically, PGE2/EP4 signals enhanced HSC autophagy through the Erk pathway. A specific PGE2/EP4 antagonist E7046 significantly inhibited M2 macrophage-mediated HSC autophagy and improved liver fibrosis and histopathology in NAFLD mice. Our study provides novel mechanistic insights into the regulation of HSC activation and liver fibrosis. Our findings suggest that the PGE2/EP4 pathway is a promising therapeutic target to prevent NASH progression into cirrhosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI